A Biotech Company Had $268 Million in Cash. After a Failed Drug Trial, It Announced a 46 Percent Workforce Cut

The biotech company is downsizing to fund another trial after a drug showed no meaningful benefit. The move comes just a year after its IPO.
techtimes

Vertex Force Opens October 3: Epigenetics and Okinawa History Power New Mecha Anime

On September 11, Anime News Network confirmed that Vertex Force, the original mecha anime from Strike Witches director Kazuhiro Takamura, will make its broadcast premiere on October 3, 2026, at 11:30 ...
Hosted on MSN

Vertex Pharmaceuticals' rally has a new engine -- and Wall Street thinks the best is still ahead

Vertex Pharmaceuticals' business could be in trouble if it faces competition in its core market. However, one of the company's most important potential competitors recently hit a clinical setback.
AOL

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

First, some background on CF. The disease is caused by mutations in the CFTR gene, which produces a defective CFTR protein. Vertex Pharmaceuticals' medicines can significantly improve CFTR function, ...
Insider Monkey

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial ...
Morningstar%2c Inc.

Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint

Vertex Pharmaceuticals shares rose after rival Sionna Therapeutics said a midstage trial of its cystic-fibrosis treatment failed to meet its primary endpoint, sending Sionna shares tumbling. Shares of ...
STAT

Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Sionna Therapeutics said Monday that its ...
FierceBiotech

Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex

Sionna shared news of the phase 2 failure, along with data from a phase 1 trial of its other drug candidates. (mrgao/iStock/Getty Images Plus) Sionna Therapeutics has axed a cystic fibrosis add-on ...
crisprmedicinenews

Vertex Reports Second Quarter 2026 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 ...
Reuters

Vertex raises annual revenue forecast on cystic fibrosis drugs strength

Aug 3 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic fibrosis treatments. The company ...
MarketScreener

Vertex Reports Second Quarter 2026 Financial Results

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies ...